| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
Cognition Therapeutics, Inc.$1.09
-0.01 (-0.92%)
C 49Pipeline Score Fair Value Biotech · Clinical
Market Cap
112.77 M
EPS
-0.26
P/E Ratio
-
Value Trade
3.07 M
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
6.12 M
Operating CF
-5.54 M
Total Assets
36.14 M
Total Liabilities
6.23 M
Equity
29.91 M
D/E Ratio
12,345
5 %
Week
5 %
1 Month
16.67 %
3 Month
-7.01 %
6 Month
-89.63 %
5 Year
-89.63 %
All Time
Cash Data
Cash Position
31.13 M
Monthly Burn
1.85 M
Runway
15 mo
Burn Trend
StableSEC Filing
May 8, 2026
Overview
Volume
1.54 M
52 Week Range
0.22 - 3.83
% held by Insiders
8.61 %
% held by Institutions
17.24 %
Enterprise Value
82.01 M
Total Shares
89.46 M
Short %
8.92 %
Float Shares
79.26 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cognition Therapeutics, Inc.
215Total events
5Upcoming
39Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 5
Event history 210
Jul 2026
◆Oral PresentationCT1812Presentation
Presentation of additional analyses from Phase 2 SHIMMER study at AAIC
dementia with Lewy bodies (DLB)source ↗
Jun 24, 2026
▲FDA Feedback ReceivedCT1812FDA Meeting
FDA agreed DLB psychosis could be approvable outcome and aligned on key aspects of pivotal trial design
dementia with Lewy bodies (DLB) psychosissource ↗
Jun 16, 2026
▲Patent GrantedCT1812IP / Competition
Notice of Allowance for composition of matter patent covering polymorphic crystalline form of zervimesine
Jun 15, 2026
◆Oral PresentationPresentation
Presentation at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
Jun 4, 2026
Jun 2026
◆Timing GuidanceCT1812Presentation
FDA formal minutes expected in June 2026
dementia with Lewy bodies with psychosissource ↗
May 20, 2026
▲FDA Feedback ReceivedCT1812FDA Meeting
FDA meeting to discuss Phase 2 results and registrational path for zervimesine in DLB psychosis
dementia with Lewy bodies with psychosissource ↗
May 14, 2026
▲Enrollment UpdateCT1812Trial
EAP enrolled 32 participants receiving zervimesine
dementia with Lewy bodiessource ↗
May 14, 2026
May 2026
◆FDA Feedback ReceivedCT1812FDA Meeting
Productive discussions with FDA regarding registrational program for DLB psychosis
dementia with Lewy bodies (DLB) psychosissource ↗
Apr 13, 2026
◆Oral PresentationPresentation
Presentation at 25th Annual Needham Virtual Healthcare Conference
Drug Pipeline Intelligence
C49
Pipeline Score $172M
Pipeline ValueFair Value
Valuation Signal9
Drugs Scored1.5x
rNPV / MCap Top 74%
Micro Cap (rank 238 of 911)
Percentile RankCognition Therapeutics, Inc. carries a moderate pipeline score (49/100), with $2.3B risk-adjusted pipeline value, led by Vortioxetine in Major Depressive Disorder (Phase 2), across $67B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vortioxetine Small molecule | Post-COVID-19 Condition | Phase 2 | NCT05047952 | 40% | $591M | COMPLETED | 149 | - | - | Feb 22, 2023 | - | Jan 16, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
zervimesine | dementia with Lewy bodies (DLB), mild-to-moderate Alzheimer’s disease | Phase 2 | 2026-06-01 | strong efficacy signals observed | Cognition Therapeutics Participating in Upcoming Investor Conferences Read More | |
zervimesine | dementia with Lewy bodies (DLB), mild-to-moderate Alzheimer’s disease | Phase 2 | 2026-06-01 | strong efficacy signals observed | Cognition Therapeutics Participating in Upcoming Investor Conferences Read More | |
zervimesine | dementia with Lewy bodies (DLB), mild-to-moderate Alzheimer’s disease | Phase 2 | 2026-06-01 | strong efficacy signals observed | Cognition Therapeutics Participating in Upcoming Investor Conferences Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CGTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CGTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CGTX▼ -38.2%on this news
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
Cognition Therapeutics announced alignment with the FDA on key aspects of a pivotal trial for zervimesine (CT1812) targeting psychosis in dementia with Lewy bodies (DLB). The FDA considers DLB psychosis an approvable outcome, and the trial is set to begin in mid-2027. Zervimesine previously demonstrated significant improvements in psychosis symptoms during Phase 2 trials.
Read more →CGTXCognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
Cognition Therapeutics has announced the receipt of a Notice of Allowance from the USPTO for a new patent covering a polymorphic crystalline form of its lead candidate, zervimesine (CT1812). This patent will protect the formulation until 2045, with a possible extension to 2050. The new form is expected to enhance the drug's stability and efficacy in treating neurodegenerative disorders.
Read more →CGTXhttps://cogrx.com COGNITION THERAPEUTICS NASDAQ: CGTX An Investigational Oral Therapy Advancing Toward Registrational Development June 2026 Jefferies Global Healthcare Conference Zervimesine in DLB Psychosis 2 COGNITION
Cognition Therapeutics (CGTX) is focusing on the development of Zervimesine, an investigational oral therapy aimed at treating dementia with Lewy bodies (DLB) psychosis. The therapy has shown promising clinical results by providing significant benefits across multiple neuropsychological domains. As the company prepares for registrational development, they face various uncertainties and risks related to future trial outcomes and market competition.
Read more →CGTX▲ +5.9%on this newsshared move
Cognition Therapeutics Participating in Upcoming Investor Conferences
Cognition Therapeutics, Inc. announced that CEO Lisa Ricciardi will present at two upcoming investor conferences in June. The presentations will focus on the company's plans for a registration program in dementia with Lewy bodies (DLB) psychosis. Webcasts of the events will be available on the company's website.
Read more →CGTXCognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis - Positive Discussion on Path Forward for Registrational Program - PURCHASE, NY
Cognition Therapeutics has completed a meeting with the FDA to discuss its investigational drug zervimesine (CT1812) for treating dementia with Lewy bodies (DLB) and psychosis. During this meeting, the company reviewed data from its Phase 2 clinical study and outlined plans for a registrational program. The FDA's feedback was described as positive, marking progress in addressing DLB psychosis. CEO Lisa Ricciardi expressed optimism about moving forward following a formal review of the meeting notes expected in June.
Read more →CGTX▲ +9.5%on this newsshared move
Why The Best Biotech Leaders Take It Personally
The article discusses the importance of personal investment by biotech leaders in their companies. It emphasizes the need for leaders to engage deeply with their work and the implications of this approach. However, the content primarily serves as a disclaimer regarding external website links.
Read more →CGTXTransforming Neurodegenerative Disease Treatment
The article primarily serves as a disclaimer regarding third-party websites linked from Cognition Therapeutics. It emphasizes that Cognition does not control or endorse the content of these external sites and encourages users to review their policies. There is no substantial information regarding the treatment of neurodegenerative diseases.
Read more →CGTXCognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Cognition Therapeutics has received a second philanthropic donation to extend its expanded access program for zervimesine, an investigational therapy for dementia with Lewy bodies. This program, which has enrolled 32 participants, will provide two years of treatment. The company is also preparing to meet with the FDA to discuss future clinical trials for zervimesine.
Read more →CGTXBlocking Toxic Oligomers: The Science and Strategy Behind Zervimesine
The article discusses the transition from the Cognition Therapeutics website to a third-party site. It emphasizes that Cognition Therapeutics does not control or endorse the content of these external sites and encourages users to review their policies. There are no specific details about Zervimesine or its scientific strategy.
Read more →CGTXSlowing Progression with Zervimesine in Dementia with Lewy Bodies
The article discusses Cognition Therapeutics and mentions Zervimesine in relation to dementia with Lewy bodies. However, it primarily serves as a disclaimer about leaving the Cognition Therapeutics website and does not provide specific information about the drug's efficacy or clinical results.
Read more →CGTX▼ -5.7%on this newsshared move
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to inform registrational plans for zervimes
Cognition Therapeutics (CGTX) reported its financial results for Q1 2026 and announced a scheduled meeting with the FDA's Division of Psychiatry for May 20, 2026, to discuss registrational plans for zervimesine in treating dementia with Lewy body psychosis. The company anticipates topline results from a Phase 2 study in early Alzheimer's disease by 2027, which may guide further clinical development. Additionally, Cognition indicated that it has sufficient cash reserves to support its operations and capital expenditures through mid-2027, though it continues to operate at a loss.
Read more →CGTX▲ +6.8%on this news
Zervimesine Slows Symptom Progression at 6 Months in Dementia with Lewy Bodies
The article mentions Zervimesine's effects on symptom progression in dementia with Lewy bodies but lacks detailed information about the study results or implications. It primarily serves as a transition to a third-party website without providing substantial content on the topic.
Read more →CGTXCognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans
Cognition Therapeutics is focusing on a faster approach to address psychosis in dementia with Lewy bodies (DLB) as it prepares for late-stage plans with Zervimesine. The article does not provide specific details about the drug's efficacy or timeline for the upcoming stages.
Read more →CGTXCognition Therapeutics to Present at Needham Virtual Healthcare Conference
Cognition Therapeutics, Inc. will present at the Needham Virtual Healthcare Conference on April 13, 2026. CEO Lisa Ricciardi will discuss the company's progress in developing treatments for Alzheimer's disease and dementia with Lewy bodies. The presentation will be available via live webcast and archived for 90 days. Cognition's lead candidate, zervimesine, has shown promise in Phase 2 trials.
Read more →CGTX▲ +17.4%on this newsshared move
Cognition Therapeutics CEO Issues Letter to Shareholders
Cognition Therapeutics' CEO Lisa Ricciardi shared a letter highlighting the company's advancements in developing zervimesine (CT1812) for dementia with Lewy bodies psychosis and Alzheimer's disease. The Phase 2 START trial is fully funded and expected to read out in late 2027. Positive results from previous trials support the ongoing development of zervimesine, with plans for future discussions with the FDA.
Read more →CGTXCognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
Cognition Therapeutics reported its financial results for 2025 and provided updates on its clinical development plans for zervimesine, particularly targeting dementia with Lewy bodies (DLB) psychosis. The company aims to meet with the FDA Division of Psychiatry in mid-2026 to discuss its registrational plan. Additionally, enrollment in the Phase 2 START trial for early Alzheimer's disease has been completed, with results expected in 2027.
Read more →CGTXZervimesine Demonstrates Symptom Slowing in Phase 2 SHIMMER Trial for Dementia with Lewy Bodies
Cognition Therapeutics has announced results from the Phase 2 SHIMMER trial for Zervimesine, which aims to address symptoms of dementia with Lewy bodies. The article does not provide specific details about the trial outcomes or implications for the drug's future. It primarily serves as a notification about leaving the Cognition Therapeutics website.
Read more →CGTX▲ +5.6%on this newsshared move
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
Cognition Therapeutics plans to release its financial results for Q4 and the full year 2025 on March 26, 2026. A conference call will follow to discuss these results and provide a business update. The company focuses on developing therapies for neurodegenerative disorders, with its lead candidate zervimesine showing promise in clinical trials.
Read more →CGTX▲ +6.5%on this news
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
Cognition Therapeutics presented findings from the Phase 2 SHIMMER study on zervimesine at the AD/PD 2026 conference. The analysis highlighted zervimesine's effectiveness in slowing the decline of neuropsychiatric symptoms in dementia with Lewy bodies (DLB). The treatment showed promise for patients who cannot tolerate traditional antipsychotics, addressing a critical need in DLB care.
Read more →CGTXAD/PD 2026 | Findings from the Phase IIa SHIMMER trial of zervimesine in mild-to-moderate DLB
The article mentions the Phase IIa SHIMMER trial of zervimesine for treating mild-to-moderate DLB. However, it primarily consists of a disclaimer regarding third-party website content and does not provide specific findings or results from the trial.
Read more →CGTXCognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
Cognition Therapeutics is advancing zervimesine (CT1812) for treating dementia with Lewy bodies (DLB) psychosis, following positive Phase 2 SHIMMER study results. The company plans to pursue a registrational path with the FDA, addressing a critical need as no approved treatments currently exist for DLB psychosis. Zervimesine has shown potential benefits without impairing motor function.
Read more →CGTXCognition lengthens Zervimesine program in DLB
Cognition Therapeutics has announced an extension of its Zervimesine program targeting dementia with Lewy bodies (DLB). The decision reflects the company's ongoing commitment to developing treatments for this challenging condition. Further details on the implications of this extension were not provided in the article.
Read more →CGTXCognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Cognition Therapeutics has extended its expanded access program for zervimesine (CT1812) in dementia with Lewy bodies, allowing for additional months of treatment. The program, which started in June 2025, has received positive feedback from participants regarding its operational aspects. The company aims to gather more long-term safety data while facilitating local monitoring by physicians. Zervimesine remains investigational and has not yet received regulatory approval.
Read more →CGTXType C Meeting with FDA Completed for Zervimesine in Dementia with Lewy Bodies
Cognition Therapeutics has completed a Type C meeting with the FDA regarding Zervimesine, a treatment for dementia with Lewy bodies. The meeting is a significant step in the regulatory process, but further details on the outcomes or next steps have not been provided in the article.
Read more →CGTXCognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
Cognition Therapeutics held a Type C meeting with the FDA to discuss the Phase 2b study of zervimesine for dementia with Lewy bodies. The meeting focused on establishing clinically meaningful endpoints for the study. The company anticipates receiving the meeting minutes soon and aims to continue collaboration with the FDA. Zervimesine is an investigational drug that targets neurodegenerative disorders.
Read more →CGTX▲ +11.8%on this news
Cognition Therapeutics Plans Phase 3 for Alzheimer’s Drug
Cognition Therapeutics is preparing to initiate a Phase 3 clinical trial for its Alzheimer's drug. The announcement indicates the company's ongoing commitment to addressing Alzheimer's disease through advanced clinical research. Further details regarding the trial's design and objectives have not been disclosed.
Read more →CGTX▼ -7.5%on this newsshared move
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Cognition Therapeutics has unveiled its Phase 3 plan for zervimesine in treating mild-to-moderate Alzheimer's disease at the CTAD conference. The FDA has endorsed the strategy of enrolling patients with lower plasma p-tau217 levels, which was shown to correlate with better treatment outcomes in Phase 2 studies. The company aims to align its global registration plans with the EMA in 2026.
Read more →CGTX▼ -7.5%on this newsshared move
Alzheimer’s Disease Pivotal Trial Design for Zervimesine Following an End-of-Phase 2 Meeting with FDA
The article discusses the pivotal trial design for Zervimesine in Alzheimer's disease following a meeting with the FDA. This meeting is crucial as it outlines the next steps in the drug's development process. The trial design will be presented at the 2025 Clinical Trials in Alzheimer’s Disease conference in San Diego, CA.
Read more →CGTX▼ -10.5%on this news
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease
Cognition Therapeutics has completed enrollment for its Phase 2 START study of zervimesine (CT1812) in early Alzheimer's disease, reaching 540 participants. The study aims to evaluate the safety and efficacy of the oral medication, with results expected after 18 months of treatment. The enrollment success is attributed to strong interest from both patients and investigators.
Read more →CGTXCognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs
Cognition Therapeutics reported a positive financial update for Q3 2025, highlighting a $30 million offering to advance Zervimesine (CT1812) development. The company has aligned with the FDA on a registrational path for Alzheimer's disease and is running an Expanded Access Program for Dementia with Lewy Bodies. Despite a net loss of $4.9 million, the company maintains sufficient cash to fund operations into 2027.
Read more →CGTX▼ -29%on this news
September 2025 Zervimesine: a Once-daily Oral Therapeutic Advancing Towards Phase 3 2 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of The Private Securities Litigati
Zervimesine (CT1812) is advancing towards Phase 3 trials, showing strong clinical signals in treating Dementia with Lewy Bodies, Alzheimer's disease, and Geographic Atrophy. The Phase 2 SHIMMER study has demonstrated favorable efficacy with robust responses in behavioral and cognitive functions. Additionally, Zervimesine exhibits a well-tolerated safety profile with minimal adverse effects reported. With promising data, the compound is expected to provide a novel oral therapeutic option for several neurodegenerative diseases.
Read more →CGTXCognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)
Cognition Therapeutics has successfully closed a $30 million registered direct offering to support the Phase 3 development of Zervimesine (CT1812), an investigational treatment for neurodegenerative disorders. The offering involved 14.7 million shares sold at $2.05 each, with Titan Partners Group acting as the placement agent. The funding aims to advance Zervimesine's clinical trials, which have shown potential in treating Alzheimer's disease and dementia with Lewy bodies.
Read more →CGTX▼ -19%on this newsshared move
Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock
Cognition Therapeutics has announced a registered direct offering of 14.7 million shares, expected to generate approximately $30 million in gross proceeds. The funds will be used primarily for preparing Phase 3 programs of zervimesine, a treatment for neurodegenerative disorders. The offering is set to close around August 29, 2025.
Read more →CGTX▲ +7.2%on this newsshared move
Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Cognition Therapeutics, Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement after its shares maintained a closing bid price of $1.00 or more for 10 consecutive business days. This compliance status was confirmed by Nasdaq on August 25, 2025. The company continues to advance its clinical programs, particularly with its lead candidate, zervimesine, in various neurodegenerative conditions.
Read more →CGTX▲ +36.1%on this news
Cognition Therapeutics and FDA Align on Zervimesine Trial for Alzheimer’s
Cognition Therapeutics has announced an alignment with the FDA regarding the Zervimesine trial for Alzheimer's disease. This collaboration indicates a step forward in the development of potential treatments for Alzheimer's. Further details on the trial's design and objectives have not been disclosed in the article.
Read more →CGTXCognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs - Discussed plans to support a pivotal Alzheimer's disease program with FDA at end-of-phase 2
Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced its financial results for Q2 2025, highlighting advancements in its clinical programs. Notably, the company has crossed 50% enrollment in its Phase 2 START study of zervimesine for Alzheimer's disease and is preparing for a pivotal meeting with the FDA regarding its registration plans. Additionally, Cognition has initiated an expanded access program for dementia with Lewy bodies. However, the company continues to report financial losses.
Read more →CGTXCognition Therapeutics’ drug shows 129% cognitive decline arrest in mild Alzheimer’s
Cognition Therapeutics has announced a significant finding regarding its drug's effectiveness in arresting cognitive decline in mild Alzheimer's patients. The reported figure indicates a 129% improvement in cognitive function. However, the article lacks detailed information about the study's methodology or results.
Read more →CGTX▼ -6.3%on this newsshared move
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease
Cognition Therapeutics presented promising data on zervimesine (CT1812) at the AAIC 2025, highlighting its efficacy in treating dementia with Lewy bodies and Alzheimer's disease. The Phase 2 SHIMMER study showed significant improvements in neuropsychiatric symptoms, while the SHINE study indicated that lower plasma p-tau217 levels correlate with better treatment responses. Zervimesine's safety and tolerability were confirmed in both studies.
Read more →CGTX▼ -6.3%on this newsshared move
Zervimesine for the Treatment of Dementia With Lewy Bodies and Alzheimer Disease
The article discusses Cognition Therapeutics and its Zervimesine treatment for Dementia with Lewy Bodies and Alzheimer Disease. However, it primarily focuses on a disclaimer regarding third-party websites, indicating that Cognition does not control or endorse external content. There are no specific details about the treatment or its efficacy.
Read more →CGTX▼ -6.3%on this newsshared move
Phase 2 Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
A Phase 2 study of CT1812 in patients with mild-to-moderate dementia with Lewy bodies was presented by Galvin et al. at the 2025 Alzheimer’s Association International Conference in Toronto. The research highlights the potential of CT1812 as a treatment option in this patient population. The presentation underscores the importance of ongoing research in dementia therapies.
Read more →CGTX▼ -14.9%on this news· ran to -30% by day 3shared move
Exploratory CSF Proteomic Analysis of a Pre-specified pTau217 Subgroup from the SHINE Clinical Trial Identifies Biomarkers Correlated with Cognitive Improvement
The article discusses a poster presentation at the 2025 Alzheimer’s Association International Conference, detailing an exploratory CSF proteomic analysis from the SHINE clinical trial. This analysis focuses on a pre-specified pTau217 subgroup and identifies biomarkers associated with cognitive improvement in Alzheimer's disease patients treated with Zervimesine. The findings may contribute to advancing understanding of Alzheimer's treatment.
Read more →CGTX▼ -14.9%on this news· ran to -30% by day 3shared move
Zervimesine (CT1812) Treatment Benefits Patients with Lower Baseline Plasma p-tau217 Across the Mild-to-Moderate AD Spectrum
The study presented at the 2025 Alzheimer’s Association International Conference highlights the benefits of Zervimesine (CT1812) for patients with mild-to-moderate Alzheimer's disease. The treatment particularly aids those with lower baseline plasma p-tau217 levels. This research contributes to the growing understanding of Alzheimer's therapies.
Read more →CGTX▼ -14.9%on this news· ran to -30% by day 3shared move
Plasma Proteomic Analysis of a Biomarker-defined Subpopulation in the SHINE Ph2 Trial to Identify Molecular Correlates to the Favorable Decrease in GFAP
The SHINE Phase 2 trial presented findings on the plasma proteomic analysis of a biomarker-defined subpopulation. The study aimed to identify molecular correlates associated with a favorable decrease in the neuroinflammatory marker GFAP in Alzheimer's disease participants treated with Zervimesine. These results were shared at the 2025 Alzheimer’s Association International Conference in Toronto.
Read more →CGTX▲ +7%on this news· ran to +32% by day 3
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease
Cognition Therapeutics published a proteomic analysis from the Phase 2 SEQUEL study, demonstrating that zervimesine (CT1812) may protect neurons and synapses in Alzheimer's patients. The study showed improvements in EEG parameters and cellular functions associated with neuronal health. Zervimesine's neuroprotective effects were confirmed through in vitro experiments, suggesting its potential as a treatment for neurodegenerative disorders.
Read more →CGTX▼ -18.9%on this news
Zervimesine in Alzheimer’s: Cognition Therapeutics and FDA Discuss Phase 2
Cognition Therapeutics is in discussions with the FDA regarding the Phase 2 study of Zervimesine for Alzheimer's disease. The article primarily focuses on the transition from the Cognition Therapeutics website to a third-party site, with no specific details provided about the drug or the discussions.
Read more →CGTX▲ +31.4%on this newsshared move
Cognition soars 35% after positive FDA meeting on Alzheimer’s asset zervimesine
Cognition Therapeutics' stock surged by 35% following a favorable meeting with the FDA concerning their Alzheimer's treatment, zervimesine. This positive reception indicates a promising outlook for the drug's development. Investors are optimistic about the potential advancements in Alzheimer's therapy as a result of this meeting.
Read more →CGTX▲ +31.4%on this newsshared move
Cognition Therapeutics Wraps Up FDA Review, Moves Closer to Phase 3 Alzheimer’s Trial
Cognition Therapeutics is nearing the completion of its FDA review process and is preparing to advance to a Phase 3 trial for its Alzheimer's treatment. This development indicates progress in their clinical research efforts. Further details on the trial's specifics and timelines are not provided in the article.
Read more →CGTXSigma-2 receptor modulators including CT1812 modulate low density lipoprotein uptake in primary rat neurons
The research presented by Knezovich et al. at Keystone 2025 highlights the role of sigma-2 receptor modulators, particularly CT1812, in influencing low-density lipoprotein uptake in primary rat neurons. This study may have implications for understanding lipid metabolism in neurological contexts.
Read more →CGTXCT1812 preserves neurons and decreases levels of neurodegeneration biomarker NfL in disease-relevant neuronal model
CT1812 demonstrated the ability to preserve neurons and reduce levels of the neurodegeneration biomarker NfL in a relevant neuronal model. This research was presented at the Keystone 2025 conference in Whistler, BC, Canada, highlighting its potential significance in neurodegenerative disease treatment.
Read more →CGTXThe sigma-2 receptor modulator and investigational therapeutic CT1812 is neuroprotective against 4-HNE-induced cell death in a disease-relevant neuronal model
The investigational therapeutic CT1812, a sigma-2 receptor modulator, has demonstrated neuroprotective properties against 4-HNE-induced cell death in a relevant neuronal model. This research was presented at the Keystone 2025 conference in Whistler, BC, Canada, highlighting its significance in the field. The findings suggest potential therapeutic applications for CT1812 in neurodegenerative diseases.
Read more →CGTXArmed with Donation from Trial Participant’s Family, Cognition Initiates Expanded Access Program for Experimental DLB Drug
Cognition Therapeutics has launched an expanded access program for its experimental drug targeting dementia with Lewy bodies (DLB). This initiative is notably backed by a donation from the family of a trial participant, highlighting community support for the research. The program aims to offer potential treatment options for patients suffering from this condition.
Read more →CGTXHow are Biomarkers Shaping Alzheimer’s Disease, and What’s Next?
The article discusses the role of biomarkers in Alzheimer's disease and hints at future developments. However, it primarily serves as a disclaimer regarding third-party content linked from the Cognition Therapeutics website. There are no specific insights or updates provided about biomarkers or Alzheimer's disease.
Read more →CGTXPhilanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies Dr. James Galvin of the University of Miami to Serve as Lead Investigator First Site Initiat
Cognition Therapeutics has launched an expanded access program for its investigational drug, zervimesine (CT1812), targeting dementia with Lewy bodies, funded by a philanthropic donation. Dr. James Galvin from the University of Miami will lead the program, which initially plans to treat around 30 patients at eight sites, starting with Banner Sun Health Research Institute. Patients will receive a daily dose of 100 mg of zervimesine for one year. Although this program offers hope for patients, zervimesine has not yet received regulatory approval, and the full safety and efficacy profile remains undetermined.
Read more →CGTX▲ +32.6%on this newsshared move
Targeting Pathogenic Oligomers: June 2025 A Disruptive Approach to the Treatment of Neurodegenerative Diseases 2 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of The
The SHINE COG0201 study highlighted Zervimesine's efficacy in treating neurodegenerative diseases by demonstrating substantial cognitive benefits particularly among participants with lower levels of plasma p-tau217. Conducted with funding from the NIH, results indicate a favorable safety profile, though some concerns were raised about discontinuation rates and liver enzyme elevations in higher doses. Next steps include a requested End-of-Phase 2 meeting with the FDA to discuss Phase 3 trials. Overall, Zervimesine shows promise as a treatment option for Alzheimer's and related disorders.
Read more →CGTX▼ -5.8%on this news· ran to +23% by day 3shared move
Episode 10: Studying the Patient-Caregiver Lived Experience in Dementia with Lewy Bodies
Episode 10 of the series explores the experiences of patients and caregivers dealing with Dementia with Lewy Bodies. Moderated by Dr. Brendan Kelley, the episode features insights from experts like Dr. Samantha K. Holden and personal stories from caregivers. Key topics include caregiver distress, symptom burden, and measuring meaningful changes in clinical trials.
Read more →CGTXCognition Therapeutics Phase 2 Trials of Zervimesine Show Promise in Dry AMD Alzheimer’s and Dementia with Lewy Bodies
Cognition Therapeutics is conducting Phase 2 trials for Zervimesine, targeting conditions such as Dry AMD, Alzheimer's, and Dementia with Lewy Bodies. The article indicates that these trials show promise, but does not provide specific results or details on the outcomes. Further information on the trials or their implications is not included.
Read more →CGTXOral Zervimesine Slows Geographic Atrophy Progression in Phase 2 Dry AMD Trial
Cognition Therapeutics has announced results from a Phase 2 trial of Zervimesine, which demonstrated a slowing of geographic atrophy progression in patients with dry age-related macular degeneration (AMD). The trial's findings may have implications for future treatment options in this area. Further details on the trial's methodology and outcomes were not provided.
Read more →CGTXCognition Therapeutics Data Shows Retinal Cell Health Impact
Cognition Therapeutics has made an announcement regarding retinal cell health impact data. However, the article does not provide specific details about the findings or implications of this data. It primarily includes a disclaimer about third-party website content and encourages users to review external site policies.
Read more →CGTX▲ +8.6%on this newsshared move
Zervimesine Robustly Slows Geographic Atrophy Lesion Growth in Latest Phase 2 MAGNIFY Data
The article discusses the Phase 2 MAGNIFY data for Zervimesine, which reportedly slows the growth of geographic atrophy lesions. However, the content primarily directs readers to a third-party website without providing detailed insights or analysis on the study results or implications.
Read more →CGTX▼ -8.8%on this newsshared move
Delineating Mechanisms of Sigma-2 Receptor Modulators in Regulating Retinal Pigment Epithelial Lipid Uptake
The article discusses a poster presentation on the mechanisms of Sigma-2 receptor modulators in regulating lipid uptake in retinal pigment epithelial cells. This research was presented at the ARVO 2025 conference in Salt Lake City, UT. The findings may have important implications for understanding retinal health.
Read more →CGTX▼ -8.8%on this newsshared move
Sigma-2 Receptor Modulation Promotes Retinal Pigment Epithelial Cell Survival Following Chronic 7-Ketocholesterol Exposure
The study presented by Hamby et al. at ARVO 2025 discusses the effects of sigma-2 receptor modulation on retinal pigment epithelial cell survival under chronic exposure to 7-ketocholesterol. The findings suggest that this modulation could provide therapeutic benefits for conditions affecting retinal cells. The research was showcased in Salt Lake City, UT.
Read more →CGTXOral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics
Cognition Therapeutics has reported results from a Phase 2 study on oral zervimesine, which demonstrated a reduction in GA lesion growth. However, the article does not provide detailed findings or implications of the study. The information is limited to a general overview without specific data or outcomes.
Read more →CGTXOral Zervimesine Reduces Geographic Atrophy Lesion Growth in Phase 2 Trial
Cognition Therapeutics has reported positive results from a Phase 2 trial of Oral Zervimesine, which demonstrated a reduction in geographic atrophy lesion growth. This development suggests the drug may be a viable treatment option for patients suffering from this condition. Further studies will be necessary to confirm these findings and assess long-term effects.
Read more →CGTX▼ -7%on this newsshared move
Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy Zervimesine treatment slowed the rate of GA lesion growth by 28.6% compared to
Cognition Therapeutics announced positive topline results from its Phase 2 MAGNIFY study for zervimesine (CT1812) in treating geographic atrophy (GA) secondary to dry AMD. The treatment showed a 28.6% reduction in lesion growth and reduced lesion size by 28.2% compared to a placebo. Despite the promising data, the study concluded ahead of its enrollment goal, with only about 100 participants enrolled. Additional outcomes regarding safety and efficacy will be released later this year.
Read more →CGTX▼ -15%on this newsshared move
Caregiver Distress: The Hidden Burden Of Dementia With Lewy Bodies — And Why Measuring It Matters
The article discusses the issue of caregiver distress associated with dementia with Lewy bodies. It highlights the importance of measuring this distress to better understand and address the challenges faced by caregivers. The content emphasizes the need for awareness and support for those affected.
Read more →CGTX▼ -15%on this newsshared move
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update - End-of-Phase 2 meeting with FDA requested for Alzheimer's disease - - Phase 2 results in dementia with Lewy bodie
Cognition Therapeutics has announced its financial results for Q1 2025, revealing a net loss of $8.5 million. The company is seeking an End-of-Phase 2 meeting with the FDA regarding its Alzheimer's disease program and has had positive Phase 2 results for dementia with Lewy bodies accepted for presentation. Additionally, Cognition's CEO noted their cash reserves will adequately support operations through the end of 2025. The company is advancing its investigational drug zervimesine in both indications.
Read more →CGTX▼ -6.5%on this news· ran to -22% by day 3
Assessing Investigational CT1812’s Impact on Tau, Amyloid, and Neurodegeneration
The article discusses the investigational drug CT1812 by Cognition Therapeutics, focusing on its potential impact on tau, amyloid, and neurodegeneration. However, it primarily serves as a disclaimer regarding third-party website content, lacking detailed information about the drug's effects or clinical findings.
Read more →CGTX▲ +5.3%on this newsshared move
2025 Is Shaping Up to Be a Big Year for This Drug Maker Working to Cure Dementia
The article discusses Cognition Therapeutics and its potential plans for 2025, particularly in relation to developing treatments for dementia. However, the content primarily focuses on a disclaimer regarding third-party websites and does not provide specific details about the company's initiatives or drug development.
Read more →CGTX▼ -6.8%on this newsshared move
Positive Impact of CT1812 Treatment on Plasma Biomarkers in Lower p-tau217 Subgroup Aligns with Clinical Benefits in Mild-to-Moderate AD Patients
The presentation at AD/PD 2025 highlighted the positive effects of CT1812 treatment on plasma biomarkers, particularly in patients with lower p-tau217 levels. These findings suggest that the treatment aligns with clinical benefits for individuals suffering from mild-to-moderate Alzheimer's disease. The results indicate a promising avenue for further research and potential therapeutic applications.
Read more →CGTX▼ -6.8%on this newsshared move
Identification of Molecular Correlates with CT1812 Treatment-related decrease in NfL CSF Levels Connected to Sigma-2 Receptor
The poster presented at AD/PD 2025 discusses the identification of molecular correlates associated with CT1812 treatment. It highlights a decrease in NfL CSF levels, which is linked to the Sigma-2 receptor. This finding may provide valuable insights into the therapeutic effects of CT1812.
Read more →CGTX▼ -6.8%on this newsshared move
CSF Proteomic Biomarker Analysis from Phase 2 Study SHINE Identified Effects of S2R Modulator CT1812 in Alzheimer’s Disease
The Phase 2 study SHINE presented findings on the S2R modulator CT1812's effects in Alzheimer's disease. The study utilized CSF proteomic biomarker analysis to identify these effects. The results were showcased at the AD/PD 2025 conference in Vienna, Austria, highlighting the potential of CT1812 in Alzheimer's research.
Read more →CGTX▼ -6.8%on this newsshared move
Identification of CSF Proteins that Correlate with Cognitive Outcomes in Participants of Phase 2 Study SHINE evaluating Effects of CT1812 in Patients with Alzheimer’s Disease
The article discusses a poster presentation at the AD/PD 2025 conference, highlighting the identification of cerebrospinal fluid (CSF) proteins that correlate with cognitive outcomes in participants of the Phase 2 SHINE study. This study evaluates the effects of CT1812 in patients with Alzheimer's disease, suggesting promising implications for future treatments.
Read more →CGTX▼ -5.2%on this news
Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update Positive Results with Zervimesine (CT1812) in Phase 2 SHIMMER Dementia with Lewy Bodies (DLB) Phase 2 SHINE Data Show Dramatic S
Cognition Therapeutics, Inc. reported positive financial results for the year ended December 31, 2024, highlighting successful Phase 2 clinical trials for Zervimesine in treating Alzheimer's disease and dementia with Lewy bodies. The company aims to transition Zervimesine into late-stage trials and is pursuing regulatory meetings with the FDA to solidify clinical protocols for both indications. As part of a strategic reshuffling, Cognition is focusing its resources on these key areas while maintaining a strong cash position into 2025.
Read more →CGTX▼ -5.4%on this news
Cognition Manuscript Publication on Oral Drug Candidate Zervimesine for Dry AMD
Cognition Therapeutics has published a manuscript regarding its oral drug candidate, Zervimesine, aimed at treating dry Age-related Macular Degeneration (AMD). The publication details the drug's potential and its development process. However, the article does not provide specific results or findings from the study.
Read more →CGTXCognition Therapeutics' Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy Masked Analysis Shows Participants Receiving Oral Zervimesine for at Least 6 M
Cognition Therapeutics reported positive results from a futility analysis of their Phase 2 trial for zervimesine (CT1812) in patients with geographic atrophy linked to dry age-related macular degeneration. The analysis showed that participants treated with zervimesine experienced a slower rate of lesion growth compared to those receiving a placebo. Following these findings, Cognition is expected to complete the study and provide a full analysis in the second quarter of 2025, while planning to engage with the FDA regarding the results.
Read more →CGTXResults from COG1201: A Proof-of-Concept Study of CT1812 in Participants with Mild-to-Moderate Dementia with Lewy Bodies
The article discusses the results from the COG1201 study, which evaluated CT1812 in participants with mild-to-moderate dementia with Lewy bodies. The findings were presented at the International Lewy Body Dementia Conference in Amsterdam, highlighting the potential of CT1812 in this specific patient population. This proof-of-concept study contributes to ongoing research in dementia treatment.
Read more →CGTXBIO CEO 2025: Cognition CEO debates policy while advancing CT1812
The article discusses Cognition Therapeutics' CEO participation in the BIO CEO 2025 event, where he debates policy issues while advancing their drug CT1812. However, the content primarily focuses on a disclaimer regarding third-party websites and does not provide substantial details about the event or the drug.
Read more →CGTXCognition Therapeutics Presents Phase 2 Results for Drug to Fight DLB at International Conference
Cognition Therapeutics has presented Phase 2 results for its drug aimed at treating Dementia with Lewy Bodies (DLB) at an international conference. The article does not provide specific details about the results or the implications of the findings. It primarily serves as a notification of the presentation rather than an analysis of the data.
Read more →CGTX▲ +6.9%on this news
Targeting Pathogenic Oligomers: January 2025 A Disruptive Approach to the Treatment of Neurodegenerative Diseases 2 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of T
The SHINE study (NCT03507790) evaluated Zervimesine (CT1812) in Alzheimer's patients and demonstrated significant cognitive preservation, particularly in individuals with lower plasma p-tau217 levels. Notably, a 95% slowing of cognitive decline was observed among participants below the median plasma p-tau217. The safety profile of Zervimesine was generally favorable, with most adverse events being mild to moderate. The company plans to meet with the FDA to discuss plans for a Phase 3 trial targeting mild-to-moderate Alzheimer’s disease patients.
Read more →CGTXCognition Therapeutics is Targeting a Critical Form of Dementia
Cognition Therapeutics is focusing on a significant form of dementia, although specific details about their approach or findings are not provided in the article. The article primarily consists of a disclaimer regarding third-party website content. As such, there is limited information available about the company's initiatives or developments.
Read more →CGTXCognition Therapeutics is Targeting a Critical Form of Dementia – Benzinga Interview
Cognition Therapeutics, led by CEO Lisa Ricciardi, shared positive outcomes from their phase 2 clinical trial of zervimesine for dementia with Lewy bodies during a Benzinga interview. The results indicate potential advancements in treating this critical form of dementia. The interview highlights the company's commitment to addressing this serious condition.
Read more →CGTXOral Small Molecule Shows Promise in Dementia with Lewy Bodies
The article discusses Cognition Therapeutics and its website's content disclaimer regarding third-party sites. It emphasizes that Cognition does not control or endorse these external sites and encourages users to review their policies. There is no specific information about the oral small molecule or its promise in treating dementia with Lewy bodies.
Read more →CGTXCT1812 Meets Primary End Point in Phase 2 SHIMMER Study for Dementia with Lewy Bodies
Cognition Therapeutics has announced that CT1812 has met its primary endpoint in the Phase 2 SHIMMER study aimed at treating dementia with Lewy bodies. This development indicates progress in the clinical evaluation of CT1812, although further details on the study's outcomes and implications are not provided in the article.
Read more →CGTX▲ +9.3%on this newsshared move
Topline Results Are In: Cognition Therapeutics’ Drug To Fight Dementia With Lewy Bodies Shows Encouraging Results In Phase 2 Trial
Cognition Therapeutics has announced positive topline results from its Phase 2 trial for a drug aimed at treating dementia with Lewy bodies. The trial results suggest that the drug may offer significant benefits, marking a hopeful advancement in the treatment of this condition.
Read more →CGTX▲ +27.5%on this newsshared move
Enhanced Cognition: Lewy body dementia phase II pumps stock
The article discusses Cognition Therapeutics and its website's transition to third-party content. It emphasizes that Cognition Therapeutics does not control or endorse the content of these external sites, advising users to review their terms and policies. The article does not provide specific details about the company's developments or stock performance.
Read more →CGTX▲ +27.5%on this newsshared move
Cognition’s phase 2 SHIMMER results finally allow dementia drug to shine
Cognition Therapeutics has reported positive results from its phase 2 SHIMMER trial for a dementia drug. These findings indicate the drug's potential effectiveness in treating dementia, marking a significant step forward for the company. The results are expected to enhance the drug's visibility and credibility in the market.
Read more →CGTX▲ +27.5%on this newsshared move
FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than state
Cognition Therapeutics has reported positive results from the phase 2a SHIMMER Trial of CT1812 for adults with dementia due to Lewy bodies. The study demonstrated clear signals of efficacy in behavioral, cognitive, functional, and motor domains, with a safety profile similar to earlier trials involving CT1812. Despite some treatment-emergent adverse events, the overall adverse events were comparable between CT1812 and placebo groups, allowing for future advancements in treatment development. The trial findings pave the way for additional planning and regulatory engagement ahead of potential phase 3 studies.
Read more →CGTXExploring Innovative Approaches in Alzheimer’s and Dementia Treatment
The article discusses Cognition Therapeutics and its website's disclaimer regarding third-party content. It emphasizes that Cognition Therapeutics does not control or endorse external sites and encourages users to review the terms and policies of those sites. There are no specific details about innovative approaches in Alzheimer's and dementia treatment provided in the text.
Read more →CGTXAn understudied dementia soon to get a pair of Phase II readouts
The article mentions Cognition Therapeutics and its upcoming Phase II readouts related to an understudied dementia. However, it primarily consists of a disclaimer regarding third-party websites and does not provide specific details about the readouts or the dementia condition itself.
Read more →CGTX▼ -10.2%on this news· ran to -23% by day 3
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update - CT1812 slowed cognitive decline by 95% in Alzheimer's disease patients with lower levels of plasma p
Cognition Therapeutics, Inc. reported its financial results for Q3 2024, highlighting a significant achievement in its Phase 2 SHINE study, where CT1812 showed a 95% reduction in cognitive decline among Alzheimer's patients with lower plasma p-tau217 levels. The company plans to request a meeting with the FDA to discuss safety, tolerability, and the design of a pivotal Phase 3 trial. Additionally, top-line results from the Phase 2 SHIMMER study for dementia with Lewy bodies are expected by the end of 2024.
Read more →CGTXAlzheimer’s Drug Shows Slower Cognitive Decline in Lower Tau Patients
The article discusses Cognition Therapeutics and its Alzheimer's drug, which reportedly shows a slower cognitive decline in patients with lower tau levels. However, the content primarily directs readers to a third-party website, lacking detailed information about the drug's efficacy or study results.
Read more →CGTXFor People with Alzheimer Disease, Treatment with an Experimental, Oral Small Molecule was Linked to Significant Slowing in Cognitive Decline
The article discusses Cognition Therapeutics and its experimental treatment for Alzheimer’s disease. It mentions a significant slowing in cognitive decline linked to the treatment. However, the content primarily focuses on a disclaimer regarding third-party websites and does not provide detailed information about the treatment or study results.
Read more →CGTXSHIMMER: Baseline Data and Early Lessons from the Ongoing Phase 2 Signal-finding Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies (DLB)
The SHIMMER study is an ongoing Phase 2 signal-finding trial evaluating CT1812 for mild-to-moderate dementia with Lewy bodies (DLB). Preliminary baseline data and insights were shared by researchers at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Madrid, Spain. The study aims to assess the efficacy of CT1812 in this patient population.
Read more →CGTXResults from COG0201: a Randomized, Placebo-controlled, Double-blind, International, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Adults with Mild-to-Moderate Alzheimer’s Disease: Focus on Pre-specified Lower p-tau217 Subgroup
The COG0201 study evaluated CT1812's safety and efficacy in adults with mild-to-moderate Alzheimer's disease. This randomized, placebo-controlled, double-blind Phase 2 trial focused on a pre-specified subgroup with lower p-tau217 levels. Results were presented at the Clinical Trials on Alzheimer's Disease conference in Madrid, highlighting the potential of CT1812.
Read more →CGTXRefining Alzheimer Treatment Through Biomarker-Based Patient Selection
Cognition Therapeutics is refining Alzheimer's treatment by focusing on biomarker-based patient selection. This approach aims to enhance the effectiveness of therapies by identifying suitable candidates for treatment. The article emphasizes the importance of patient selection in clinical outcomes for Alzheimer's therapies.
Read more →CGTX▲ +5.1%on this newsshared move
Neuroprotective effect of Sigma-2 modulator CT2074 in a mouse model of ocular hypertension
The article discusses the neuroprotective effects of the Sigma-2 modulator CT2074 in a mouse model of ocular hypertension. Conducted by Donkor et al., the study highlights the potential of CT2074 as a therapeutic option for neuroprotection in ocular conditions. The findings are published in Experimental Eye Research, indicating a significant advancement in this area of research.
Read more →CGTX▲ +6.2%on this newsshared move
Commentary on plasma p-tau217 subgroup analysis from Phase 2 Alzheimer’s disease study
The webinar on October 30 discussed the SHINE study results presented at the CTAD meeting, focusing on the impact of plasma p-tau217 levels on cognitive function in Alzheimer’s patients. The analysis revealed that patients with lower p-tau217 levels taking CT1812 maintained cognitive function, while placebo patients declined. The findings suggest a promising avenue for identifying patients who could benefit from CT1812 in future trials.
Read more →CGTXEpisode 9: Executing Clinical Research in Dementia with Lewy Bodies (DLB)
Episode 9 of the series features a discussion on executing clinical research in Dementia with Lewy Bodies (DLB). Moderated by Anthony Caggiano, the episode includes insights from experts such as Dr. James E. Galvin and Dr. Lawrence S. Honig. Key topics include comparisons between Alzheimer's disease and DLB, as well as the SHIMMER study design and metrics for success.
Read more →CGTXCognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference
Cognition Therapeutics will be participating in the Roth Healthcare Opportunities Conference. The announcement indicates the company's engagement with investors and stakeholders in the healthcare sector. However, specific details regarding their presentation or agenda at the conference were not provided.
Read more →CGTX▼ -6.1%on this newsshared move
Cognition Therapeutics Supports Lewy Body Dementia Awareness Month
Cognition Therapeutics is promoting awareness for Lewy Body Dementia during the designated awareness month. This initiative aims to educate the public about the condition and its impact on patients and families. The company emphasizes the significance of understanding Lewy Body Dementia to foster better support and resources.
Read more →CGTX▼ -6.1%on this newsshared move
Targeting Amyloid Beta Oligomers: A Disruptive Approach to the Treatment of CNS Disorders September 2024 2 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of The Privat
The article discusses the advancements surrounding CT1812, a therapeutic targeting amyloid beta oligomers, with promising results in Alzheimer's disease and dry age-related macular degeneration (AMD). The drug is noted for its consistent efficacy and patient-friendly oral administration format, which avoids the limitations associated with IV therapies. It is currently being studied in phase 2 trials for its effectiveness in treating several CNS disorders, including dementia with Lewy bodies and dry AMD. The potential for CT1812 to enter the market first for geographic atrophy further highlights its significance in treatment advancements.
Read more →CGTX▼ -6.2%on this news· ran to -20% by day 1
Sigma-2 Receptor Modulators Alter Low-density Lipoprotein Receptor-mediated Lipid Trafficking in Retinal Pigmented Epithelial Cells
The article discusses a presentation by Lizama et al. on the effects of Sigma-2 receptor modulators on lipid trafficking in retinal pigmented epithelial cells. This research was showcased at the 2024 Keystone Conference focused on dry age-related macular degeneration. The findings may contribute to new therapeutic strategies for this condition.
Read more →CGTX▼ -10.9%on this news
Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences
Cognition Therapeutics has announced its participation in investor conferences scheduled for September 2024. The announcement indicates the company's ongoing engagement with investors and the broader financial community. However, specific details regarding the conferences or topics to be discussed were not provided in the article.
Read more →CGTXTheir Alzheimer’s treatment worked
The article mentions Cognition Therapeutics' Alzheimer's treatment but lacks specific details about its effectiveness or outcomes. It primarily discusses the transition to a third-party website, offering no substantial information on the treatment itself. As a result, the overall context remains unclear and uninformative.
Read more →CGTXTargeting Amyloid Beta Oligomers: A Disruptive Approach to the Treatment of Alzheimer's Disease August 2024 2 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of The Pri
CT1812, a novel treatment targeting amyloid beta oligomers, is under investigation for Alzheimer's disease and related dementias. Early studies have reported consistent cognitive improvements in patients with mild to moderate forms of these diseases. CT1812 is designed for oral administration, bypassing the need for IV therapy, and aims to become a first-in-class option for dementia with Lewy bodies. Financially, the company holds $28.5M in cash, which should sustain operations into the second quarter of 2025 while they await key clinical trial results by the end of 2024.
Read more →CGTXSmall molecule oligomer antagonist for Alzheimer’s disease boosts brain connectivity
The article discusses Cognition Therapeutics and its small molecule oligomer antagonist for Alzheimer's disease. However, it primarily focuses on a disclaimer regarding third-party websites and does not provide specific details about the drug's efficacy or research findings. Therefore, the content lacks substantial information on the topic.
Read more →CGTXCT1812 slows cognitive decline in proof-of-concept clinical trial
Cognition Therapeutics has announced a proof-of-concept clinical trial for CT1812, which aims to slow cognitive decline. The trial's results are expected to provide insights into the drug's efficacy. Further details on the trial's design and outcomes have not been disclosed.
Read more →CGTXCognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
Cognition Therapeutics has released findings from the Phase 2 SEQUEL study of CT1812, which targets Mild-to-Moderate Alzheimer's Disease. The published EEG results indicate potential benefits of the treatment. This research contributes to the ongoing efforts to find effective therapies for Alzheimer's patients.
Read more →CGTXCT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer’s disease
The article discusses a meta-analysis of cerebrospinal fluid (CSF) proteomic findings from two Phase 2 clinical trials focusing on CT1812 in Alzheimer's disease. This research aims to identify a biomarker signature that could enhance understanding and treatment of the disease. The findings may contribute to better diagnostic and therapeutic approaches in Alzheimer's care.
Read more →CGTXCognition Stays the Course
The article primarily serves as a disclaimer regarding the use of third-party websites linked from Cognition Therapeutics. It emphasizes that Cognition Therapeutics does not control or endorse the content of these external sites and encourages users to review their policies. There are no specific news updates or developments mentioned.
Read more →CGTXCognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update
Cognition Therapeutics has released its financial results for the second quarter of 2024, along with an update on its business and clinical activities. The report highlights key financial metrics and ongoing projects, although specific details on clinical advancements were not disclosed. This update is part of the company's regular reporting cycle.
Read more →CGTXCognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update - Proof-of-Concept Phase 2 SHINE Trial Demonstrates ~40% Mean Improvement in ADAS-Cog 11 vs Placebo a
Cognition Therapeutics, Inc. reported its financial results for the second quarter of 2024, highlighting significant improvements from the Phase 2 SHINE trial in patients with mild-to-moderate Alzheimer's disease. The trial demonstrated a ~40% mean improvement in cognitive measures compared to a placebo. However, the company also reported increased financial losses, with a net loss of $7.0 million for the quarter. Looking ahead, Cognition plans to announce results from its SHIMMER study in mild-to-moderate dementia with Lewy bodies by the end of 2024.
Read more →CGTX▼ -9.8%on this newsshared move
A Pilot Electroencephalography Study of the Effect of CT1812 Treatment on Synaptic Activity in Patients with Mild to Moderate Alzheimer’s Disease
A recent pilot study investigated the effects of CT1812 on synaptic activity in patients with mild to moderate Alzheimer's disease. Conducted by Vijverberg et al., the research aims to explore the treatment's potential benefits. The findings could provide insights into new therapeutic strategies for managing Alzheimer's.
Read more →CGTX▼ -10%on this newsshared move
Cognition Therapeutics to Report Second Quarter 2024 Financial Results
Cognition Therapeutics is set to report its financial results for the second quarter of 2024. The announcement indicates a routine update on the company's financial performance. No specific details about the results or expectations have been provided in the article.
Read more →CGTX▼ -10%on this newsshared move
Supportive Evidence for CT1812 as Treatment for Alzheimer Disease
Cognition Therapeutics has provided a notice regarding the transition to a third-party website. The company disclaims responsibility for the content found on these external sites and encourages users to review their terms of use and privacy policies, which may differ from Cognition's own.
Read more →CGTX▼ -43.9%on this news· ran to -62% by day 3
Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients
Cognition Therapeutics has reported positive results from its Phase 2 SHINE trial, demonstrating consistent improvements in cognitive outcomes for patients with mild-to-moderate Alzheimer's disease. The trial evaluated the efficacy of once-daily oral CT1812, which appears to be a promising treatment option. These findings may have significant implications for Alzheimer's therapy.
Read more →CGTX▼ -43.9%on this news· ran to -62% by day 3shared move
Exploratory CSF Proteomics Biomarker Outcomes of The Phase 2 Clinical Trial SHINE to Assess The Effects of CT1812 in Alzheimer’s Patients
The article discusses the exploratory outcomes of the Phase 2 SHINE trial assessing CT1812 in Alzheimer's patients. Results were presented at the 2024 Alzheimer's Association International Conference in Philadelphia. The findings focus on CSF proteomics biomarkers, which may provide insights into the treatment's effects on Alzheimer's disease.
Read more →CGTX▼ -43.9%on this news· ran to -62% by day 3shared move
CSF Phosphoproteomics Biomarker Analysis from the Phase 2 Clinical Trial SHINE to Elucidate the Role of CT1812 in Alzheimer’s Disease
The article discusses a presentation at the 2024 Alzheimer’s Association International Conference regarding CSF phosphoproteomics biomarker analysis from the Phase 2 SHINE clinical trial. The study aims to elucidate the role of CT1812 in treating Alzheimer’s disease. This research highlights the potential of CT1812 as a therapeutic option.
Read more →CGTX▼ -43.9%on this news· ran to -62% by day 3shared move
Top-Line CSF Biomarker Outcomes From The Phase 2 Clinical Trial SHINE In Alzheimer’s Patients
The article discusses the top-line results of the SHINE Phase 2 clinical trial, which investigated cerebrospinal fluid (CSF) biomarkers in Alzheimer's patients. The findings were presented at the 2024 Alzheimer's Association International Conference in Philadelphia. These results are significant for advancing Alzheimer's research and potential treatments.
Read more →CGTX▼ -43.9%on this news· ran to -62% by day 3shared move
Results from COG0201: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild-to-Moderate Alzheimer’s Disease
The study COG0201 evaluated the safety and efficacy of CT1812 in patients with mild-to-moderate Alzheimer's disease. Conducted as a randomized, double-blind, placebo-controlled trial, the results were presented at the 2024 Alzheimer’s Association International Conference in Philadelphia. The findings suggest potential benefits of CT1812 for this patient population.
Read more →CGTX▼ -43.9%on this news· ran to -62% by day 3shared move
Results from the Proof-of-Concept Phase 2 ‘SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease​
Cognition Therapeutics (CGTX) announced positive results from the Phase 2 'SHINE' study of CT1812 for mild-to-moderate Alzheimer's disease. The study found significant slowing in cognitive decline among treated subjects compared to placebo, with reduction percentages in key cognitive metrics reaching up to 39%. Additionally, CT1812 demonstrated a favorable safety profile, although some cases of elevated liver enzymes were noted at the 300mg dosage. These results provide compelling evidence for advancing CT1812 into further studies.
Read more →CGTX▲ +12.9%on this news· ran to -52% by day 3shared move
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
Cognition Therapeutics will host an investor webcast on July 29, 2024, at 8:30 am ET. The event will focus on the results from the Phase 2 SHINE study of CT1812, which targets Mild-to-Moderate Alzheimer’s Disease. This webcast aims to provide insights into the drug's efficacy and potential impact.
Read more →CGTX▲ +9%on this news
Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC
Cognition Therapeutics announced that results from their Phase 2 SHINE study of CT1812 in patients with mild-to-moderate Alzheimer's disease have been accepted for presentation at the Alzheimer's Association International Conference (AAIC). This acceptance underscores the importance of their research in addressing Alzheimer's disease.
Read more →CGTXAn interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer’s disease
The article discusses an interim exploratory analysis of proteomics biomarkers from a phase 2 clinical trial evaluating CT1812's effects on Alzheimer's disease. Conducted by Lizama et al., the study aims to provide insights into the potential impact of CT1812 in treating this condition. The findings may contribute to future Alzheimer's research and treatment strategies.
Read more →CGTX▼ -7.6%on this news
Amyloid Remains a Key Target in Next-Generation Alzheimer’s Treatments
The article discusses the ongoing focus on amyloid as a target in developing next-generation Alzheimer's treatments. Cognition Therapeutics emphasizes the importance of understanding third-party content related to this area. However, the article does not provide specific details or updates on treatments or research.
Read more →CGTX▲ +15%on this newsshared move
Cognition adding $11.5M in public offering for Alzheimer’s drug
Cognition Therapeutics is initiating a public offering to raise $11.5 million for its Alzheimer's drug. The offering reflects the company's ongoing efforts to fund its research and development initiatives. Further details about the offering and its implications for the company's future projects were not provided in the article.
Read more →CGTXCharacterization of Human iPSC-derived Neurons as an <em>In Vitro</em> Model to Investigate Sigma-2 Receptor Functions
The article discusses a poster presentation by Caldwell et al. at the 2024 Keystone Conference on Neurodegenerative Diseases. The research focuses on characterizing human iPSC-derived neurons as an in vitro model to investigate the functions of sigma-2 receptors. This innovative approach may contribute to understanding neurodegenerative diseases.
Read more →CGTX▲ +5.1%on this news· ran to +21% by day 1
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer’s Disease
Cognition Therapeutics has released a new episode of its podcast titled 'Conversations,' focusing on the topic of protecting synapses from amyloid toxicity in Alzheimer's disease. The episode aims to provide insights into the ongoing challenges and research related to Alzheimer's. Further details about the podcast's content were not provided in the article.
Read more →CGTXEpisode 8: Protecting the Synapse from Amyloid Toxicity in Alzheimer’s Disease
The episode features a discussion on protecting synapses from amyloid toxicity in Alzheimer's disease. Moderated by experts from Cognition Therapeutics, it highlights findings from the SEQUEL study and clinical observations related to the drug CT1812. The ongoing Phase 2 study of CT1812 is also discussed, showcasing its potential in Alzheimer's treatment.
Read more →CGTXCognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
Cognition Therapeutics has reported its financial results for the first quarter of 2024. The article primarily focuses on the company's financial performance and business updates. However, it does not provide specific details about the results or any significant developments. The content is largely informational regarding the company's website policies.
Read more →CGTXCognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update - Topline Results from SHINE Study in Mild-to-Moderate Alzheimer's Expected Mid-2024 - - SHIMMER Study in Dementia
Cognition Therapeutics has announced its financial results for the first quarter of 2024, revealing a net loss of $9.2 million. The company successfully completed the enrollment of 130 participants in the Phase 2 SHIMMER study for dementia with Lewy bodies and is preparing to release topline results from the SHINE study for Alzheimer's disease in mid-2024. Additionally, Cognition raised $11.9 million through a public offering, indicating a robust financial strategy amidst increasing development costs.
Read more →CGTXDifferentiated retinal pigment epithelial cells as a model for uncovering sigma-2 receptor functions and novel therapeutics for dry AMD
The article discusses a presentation at the 2024 Association for Research in Vision & Ophthalmology, focusing on differentiated retinal pigment epithelial cells. This research aims to uncover the functions of sigma-2 receptors and explore novel therapeutics for dry age-related macular degeneration (AMD). The findings could lead to significant advancements in AMD treatment.
Read more →CGTXCognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
Cognition Therapeutics has completed enrollment for its Phase 2 SHIMMER study, which is investigating the efficacy of CT1812 in patients with mild-to-moderate dementia with Lewy bodies. This marks a significant step in the clinical development of CT1812, aimed at addressing this challenging condition. Further results from the study will be awaited to assess the drug's potential.
Read more →CGTXNavigating Growth In Biotech: A First-Person Insight
The article discusses Cognition Therapeutics' stance on third-party websites. It emphasizes that the company does not control or endorse the content found on these external sites and encourages users to review their terms and privacy policies. This reflects the company's commitment to transparency and user awareness.
Read more →CGTXCognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update - Topline Results from SHINE Study in Mild-to-Moderate Alzheimer's Expected mid-2024 - - On Track to Report Topline Results from
Cognition Therapeutics has released their Year End 2023 financial results and business update, highlighting significant accomplishments in clinical studies focused on neurodegenerative disorders. The SHINE study's topline results for mild-to-moderate Alzheimer's disease are anticipated in mid-2024, while the SHIMMER study in mild-to-moderate dementia with Lewy bodies is set for the second half of 2024. The company has successfully raised capital to extend its operational runway and reported a net loss increase, reflecting ongoing investments in research and development.
Read more →CGTX▼ -6.6%on this news
Finding the Right Patients: Q&A With Lisa Ricciardi, CEO of Cognition Therapies, Inc.
The article features a Q&A with Lisa Ricciardi, CEO of Cognition Therapies, Inc., discussing patient selection. It emphasizes the importance of finding the right patients for their therapies. However, the text primarily serves as a disclaimer regarding third-party websites and does not provide specific insights into the company's operations or strategies.
Read more →CGTX▲ +8.2%on this news
Identification of New Pharmacodynamic Biomarkers of CT1812 that Correlate with Favorable Functional Connectivity of the Brain
The e-poster presented by Di Caro et al. at the AD/PD™ 2024 conference highlights the identification of new pharmacodynamic biomarkers associated with CT1812. These biomarkers show a correlation with favorable functional connectivity in the brain, suggesting potential implications for Alzheimer's and Parkinson's disease treatments.
Read more →CGTX▲ +8.2%on this newsshared move
Proteomic Analysis from Alzheimer’s Patients in SPARC Clinical Trial to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812
The article discusses a poster presentation at the AD/PD 2024 conference, detailing a plasma proteomic analysis from Alzheimer's patients involved in the SPARC clinical trial. The study aims to identify pharmacodynamic biomarkers for the S2R modulator CT1812. This research could enhance understanding of Alzheimer's treatment efficacy.
Read more →CGTX▲ +8.2%on this newsshared move
Analysis of CSF Samples from a Phase 2 Clinical Trial in Alzheimer’s Patients Show that CT1812 can Modulate α-synuclein
A recent analysis of cerebrospinal fluid (CSF) samples from a Phase 2 clinical trial indicates that CT1812 can effectively modulate α-synuclein in Alzheimer's patients. This research was presented at the AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference held in Lisbon, Portugal. The findings suggest promising implications for future Alzheimer's treatments.
Read more →CGTXTransmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease
The article discusses the identification of transmembrane protein 97 as a potential synaptic receptor for amyloid beta in Alzheimer's disease. This discovery may provide new insights into the mechanisms of Alzheimer's and open avenues for targeted therapies. The research highlights the importance of this protein in the context of neurodegeneration.
Read more →CGTX▼ -6.6%on this news
A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease
A pilot study led by van Dyck et al. investigates the impact of CT1812 on synaptic density and other biomarkers in Alzheimer's disease. The research aims to assess the treatment's efficacy in enhancing cognitive functions. Results from this study could provide valuable insights into new therapeutic approaches for Alzheimer's.
Read more →CGTXCognition Therapeutics CEO shares update on MAGNIFY Trial enrollment and the company’s work on dry AMD
The article discusses an update from Cognition Therapeutics regarding the MAGNIFY Trial enrollment and their ongoing efforts related to dry Age-related Macular Degeneration (AMD). However, the content primarily redirects to third-party sites and does not provide specific details about the trial or the company's work.
Read more →CGTXThe field allows up to 17 characters.
The article discusses the specifications for a naming format that allows for up to 17 characters, including prefixes, sequence numbers, and suffixes separated by hyphens. Various metadata fields, such as Entity Registration Name, Entity Tax Identification Number, and trading symbols are also outlined. Furthermore, details regarding forms filed with the SEC and the use of specific boolean flags are provided. Overall, this information appears technical and is related to compliance and filing standards but does not provide any actionable insights regarding CGTX.
Read more →CGTXEpisode 7: Quantitative EEG – Effects of CT1812 on Measures of Synaptic Function in Alzheimer’s Disease
The article discusses Episode 7 of a series focusing on CT1812's effects on synaptic function in Alzheimer's disease. Moderated by Dr. Anthony Caggiano, it features insights from prominent researchers including Dr. Willem de Haan and Dr. Philip Scheltens. Key findings from the SEQUEL study are highlighted, emphasizing the potential of EEG in neurodegenerative diseases.
Read more →CGTX▲ +6.5%on this news
A transcriptomic analysis to investigate the role of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer’s disease
The article discusses a transcriptomic analysis of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer's disease. The findings were presented at the Society for Neuroscience annual meeting in November 2023. This research aims to enhance understanding of the role these modulators may play in treating Alzheimer's.
Read more →CGTX▲ +6.5%on this newsshared move
A proteomic analysis to elucidate the role of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer’s disease
The article discusses a poster presentation by Cho E and colleagues at the Society for Neuroscience annual meeting in November 2023. The research focuses on the role of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer's disease. This study aims to provide insights into potential therapeutic strategies for Alzheimer's.
Read more →CGTX▲ +6.5%on this newsshared move
Exploratory omics study reveals potential roles of sigma-2 receptor modulators in AAV1/2A53T-aSyn rat model of Parkinson’s disease
An exploratory omics study presented at the Society for Neuroscience annual meeting highlights the potential roles of sigma-2 receptor modulators in a rat model of Parkinson's disease. The findings suggest these modulators could have therapeutic implications. This research adds to the growing body of knowledge regarding treatment options for Parkinson's.
Read more →CGTX▲ +6.5%on this newsshared move
Unbiased proteomic and transcriptomic analysis of Sigma-2 receptor modulation in an in vivo model of synucleinopathy
The article discusses a presentation by Lizama et al. at the Society for Neuroscience annual meeting in November 2023. The research focuses on the unbiased proteomic and transcriptomic analysis of Sigma-2 receptor modulation in an in vivo model of synucleinopathy. This study may contribute to the understanding of synucleinopathy and its underlying mechanisms.
Read more →CGTX▼ -6.4%on this news
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Phase 2 trials in mild-to-moderate Alzheimer's disease and dementia with Lewy bodies advancing Clinical site initiation und
Cognition Therapeutics announced its third-quarter 2023 financial results, highlighting significant progress in its clinical trials for Alzheimer's disease and dementia with Lewy bodies. The company is advancing its Phase 2 SHINE and START trials, with the latter allowing for combination therapy with lecanemab. CFO Lisa Ricciardi expressed optimism about the company’s future, citing two anticipated data readouts in 2024 and a strong cash position. Despite a net loss reported for the quarter, Cognition is focused on advancing its innovative treatment pipeline.
Read more →CGTXProteomic Analysis in a Phase 2 Clinical Trial Studying CT1812 to Identify CSF and Plasma Pharmacodynamic Biomarkers and Molecular Correlates of EEG in Alzheimer’s Patients
The article discusses a poster presentation on a Phase 2 clinical trial of CT1812, focusing on identifying pharmacodynamic biomarkers in cerebrospinal fluid (CSF) and plasma, as well as molecular correlates of EEG in Alzheimer's patients. This research was presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, Massachusetts, in October 2023.
Read more →CGTXProteomic Analysis of Plasma in a Phase 2 Clinical Trial in Alzheimer’s Patients to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812
A recent poster presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference highlights a Phase 2 clinical trial analyzing plasma proteomics in Alzheimer's patients. The study focuses on identifying pharmacodynamic biomarkers associated with the S2R modulator CT1812. This research aims to enhance the understanding of treatment effects in Alzheimer's disease.
Read more →CGTXAs Biopharma Giants Reshape the Field, Cognition Therapeutics Sees a Place for Its Alzheimer’s Drug
Cognition Therapeutics is positioning itself within the competitive landscape of Alzheimer's drug development. The article highlights the company's strategic approach amidst the reshaping of the biopharma field by larger companies. However, specific details about their drug or clinical advancements are not provided.
Read more →CGTXDisease - modifying medicines for neurodegenerative disorders
Cognition Therapeutics (CGTX) is exploring CT1812, an oral therapy aimed at addressing neurodegenerative diseases such as Alzheimer's and Dementia with Lewy Bodies. The company emphasizes its potential to modify disease progression through an innovative mechanism targeting amyloid oligomers. While the near-term development pipelines include multiple clinical trials, there are numerous risks associated with regulatory approvals and financial uncertainties affecting future performance. Additionally, the rising demographic challenges and high caregiving costs are pressing issues in the context of neurodegenerative disease treatment.
Read more →CGTXEpisode 6: Geographic Atrophy – New Strategies to Protect the Retina
The episode features discussions on new strategies to protect the retina from geographic atrophy, highlighting advances in understanding the condition. Experts share insights on the role of complement in dry AMD and evidence supporting sigma-2 modulation. The MAGNIFY Trial is also mentioned as part of the ongoing research.
Read more →CGTXDisease-modifying medicines for neurodegenerative disorders Perspective from a pre-Commercial Company August 2023 2 Confidential • Why we work in age-related neurodegenerative conditions • What we are doing
Cognition Therapeutics, Inc. is advancing its candidate CT1812 for the treatment of Alzheimer's disease, noting significant improvements in cognitive function and brain atrophy in ongoing clinical trials. Their research strategy includes a focus on identifying candidate biomarkers and planning for Phase 3 trials. The company aims to address patient care and caregiver needs through its innovative oral therapy, which also features a strong intellectual property position. Financial support for its initiatives has been robust, although their cash runway is estimated to last only until late 2024, raising some concerns about future funding.
Read more →CGTXCognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update Announced Positive Topline Results from CT1812 Phase 2 SEQUEL Study in Mild-to-Moderate Alzheimer's Disease Commenced Recruitment f
Cognition Therapeutics reported positive topline results from its CT1812 Phase 2 SEQUEL study targeting mild-to-moderate Alzheimer's disease. The company has commenced recruitment for a 540-patient Phase 2 START Trial, further emphasizing its commitment to addressing neurodegenerative disorders. Financial results showed a net loss of $4.7 million for the second quarter, slightly improved from the previous year. Continued advancements in research and clinical trials signify promising developments for the company's lead drug candidate, CT1812.
Read more →CGTX▲ +9.2%on this news
There’s finally hope for patients with Alzheimer’s disease
The article indicates a potential positive development for Alzheimer's disease patients, but it primarily consists of a disclaimer regarding third-party websites. There is no specific information provided about the advancements or research related to Alzheimer's treatment.
Read more →CGTXBrain transcriptomic and proteomic analyses in an <em>in vivo</em> AD model further elucidate the role of the sigma-2 receptor modulator CT1812 in Alzheimer’s disease
The study presented at the 2023 Alzheimer’s Association International Conference highlights the role of the sigma-2 receptor modulator CT1812 in Alzheimer's disease. Through brain transcriptomic and proteomic analyses in an in vivo model, researchers aim to deepen the understanding of CT1812's effects. This research could pave the way for new therapeutic strategies in treating Alzheimer's.
Read more →CGTX▼ -12.8%on this news· ran to -30% by day 1
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer's Disease Results Show Positive Treatment Effect of CT1812 on Global and Regional Brain Activity Ma
Cognition Therapeutics, Inc. announced positive topline results from its Phase 2 SEQUEL study of CT1812 for treating mild-to-moderate Alzheimer's disease. The study demonstrated positive effects on brain activity, showing participants on CT1812 had a numerical reduction in relative theta power compared to placebo. Although these results did not reach statistical significance, they indicate a potentially beneficial impact on cognitive function. The study also confirmed the safety profile of CT1812, with no severe adverse events reported.
Read more →CGTXCognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update Completed enrollment for Phase 2 SEQUEL trial in mild-to-moderate Alzheimer's disease (AD); topline results expected 2Q 202
Cognition Therapeutics, Inc. reported its financial results for Q1 2023, highlighting the completion of patient enrollment in the Phase 2 SEQUEL trial for Alzheimer's disease and FDA clearance for two additional Phase 2 trials. The company announced a net loss of $6.2 million for the quarter and continued to secure funding through a share purchase agreement. The anticipated topline results for the SEQUEL trial are expected in the second quarter of 2023, along with the ongoing enrollment for the SHINE trial in Spain. Management emphasizes a strategic focus on advancing clinical studies for its lead candidate, CT1812.
Read more →CGTXDeveloping disease-modifying medicines for degenerative disorders Analyst Breakfast April 2023 2 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of The Private Securiti
CGTX is advancing its investigational therapy CT1812, targeting geographic atrophy related to dry age-related macular degeneration (AMD). The company is preparing for a Phase 2 clinical trial to assess the efficacy of CT1812 in patients suffering from this condition. Additionally, CT1812 is involved in multiple clinical trials for Alzheimer's disease, and the firm has secured significant grant funding to support its studies. Overall, CGTX is positioned for potential breakthroughs in treating these degenerative disorders.
Read more →CGTXCognition Therapeutics Presents Proteomic Biomarker Data Demonstrating Prominent Effects of CT1812 in Altering Underlying Alzheimer's Disease Processes
Cognition Therapeutics, Inc. presented promising results from a meta-analysis of two clinical trials involving their drug CT1812 for Alzheimer's disease. The analysis showed significant effects on proteins linked to Alzheimer's pathology, particularly on levels of clusterin and prion protein, which may influence neurotoxicity and cognitive function. The findings suggest that CT1812 could help alter disease processes associated with Alzheimer's progression. The poster detailing these findings is being presented at an international conference and will be available online after the event.
Read more →CGTXCognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update - Completed enrollment of CT1812 Phase 2 SEQUEL study for mild-to-moderate Alzheimer's disease - Received FDA clearance for Phas
Cognition Therapeutics, Inc. has reported its financial results for the year ending December 31, 2022, highlighting significant advancements in its clinical programs. They completed enrollment in the Phase 2 SEQUEL study for mild-to-moderate Alzheimer's disease and received FDA clearances for additional studies involving CT1812. The company also secured a commitment for up to $35 million in equity financing to support ongoing projects. Despite a net loss of $21.4 million for the year, Cognition aims to effectively execute its clinical agenda and capitalize on its momentum in 2023.
Read more →CGTXCognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry
Cognition Therapeutics has announced that the FDA has cleared its IND application for CT1812, aimed at treating geographic atrophy secondary to dry age-related macular degeneration. The upcoming Phase 2 MAGNIFY trial is set to enroll around 246 participants to evaluate the drug's efficacy in slowing vision loss. The company believes that CT1812's innovative mechanism in protecting retinal cells may benefit millions affected by dry AMD. Despite the enthusiasm, CT1812 is still in the investigational stage and has yet to receive formal approval.
Read more →CGTX▲ +6.4%on this news
Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer's Disease
Cognition Therapeutics, Inc. has received FDA clearance to conduct a Phase 2 study of its investigational drug, CT1812, in patients with early Alzheimer's disease. The trial, named START, will involve approximately 540 participants and will measure the efficacy and safety of the drug over an 18-month period. Funded by an $81 million grant from the National Institute on Aging, this initiative aims to explore CT1812's potential to prevent cognitive decline. The study represents a significant step forward in Alzheimer's therapeutic research, leveraging collaboration with the Alzheimer's Clinical Trials Consortium.
Read more →CGTX▼ -5.5%on this news
Developing disease - modifying medicines for degenerative disorders November 2022 2 FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements within the meaning of The Private Securities Litiga
Sigma - 2 receptor modulators rescue POS trafficking deficits in RPE cell - based models of dry AMD. Poster presen ted at: 2022 ARVO 27 Planned Phase 2 (COG2201) will Assess CT1812 in dry AMD and Measurable Geographic Atrophy Assessments such as: Change in GA lesion Low luminance
Read more →CGTX▼ -6.1%on this newsshared move
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update - SHINE Alzheimer's Trial Expands to European Sites - - SEQUEL Alzheimer's Trial Awarded Additional NIA Grant to Complete -
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update Trial Expands to European Sites - - SEQUEL Alzheimer's Trial Awarded Additional NIA Grant to Complete - - Over 50% of SHIMMER Dementia with Lewy Bodies Study Sites Active - NY
Read more →CGTXDeveloping disease- modifying medicines for degenerative disorders August 2022 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All state
J Neurosci Res. 2021. doi: 10.1002/jnr.24782 21 - Principal investigator: James E. Galvin, MD, MPH, professor of neurology and director of the Comprehensive Center for Brain Health - Phase 2 trial ongoing - Participant dosing underway - U Miami and 20+ academic sites - Archived D
Read more →CGTXCognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update Ongoing patient dosing in SHIMMER Study for DLB and SHINE Study for Alzheimer's Disease Positive Preliminary Data for Dry
Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update Ongoing patient dosing in SHIMMER Study for DLB and SHINE Study for Alzheimer's Disease Positive Preliminary Data for Dry AMD Program Presented at ARVO 2022 Proteomics Data fr
Read more →CGTX▲ +5.5%on this news· ran to -17% by day 3
Disease - modifying medicines for degenerative disorders JMP Securities Life Sciences Conference
Disease - modifying medicines for degenerative disorders JMP Securities Life Sciences Conference June 16, 2022 2 This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements contained in this
Read more →CGTX▼ -7.4%on this news
Cognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update Treatment Commences in Second Cohort of Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease Data Presented at Scien
Cognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update Treatment Commences in Second Cohort of Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease Data Presented at Scientific Conferences Further Validate the Potential of -2
Read more →CGTX▼ -10.4%on this news
Cognition Therapeutics Reports Year End 2021 Financial Results and Provides Business Update - Well capitalized from $52 million IPO and $169 million in grant funding - - Established clinical program in Alzheimer's diseas
Cognition Therapeutics Reports Year End 2021 Financial Results and Provides - Well capitalized from $52 million IPO and $169 million in grant funding - - Established clinical program in Alzheimer's disease enhanced by new DLB study and dry AMD program - Conference Call and
Read more →CGTXEXPERIMENTAL THERAPEUTIC CT1812 DEMONSTRATES TARGET ENGAGEMENT IN A PHASE 1b CLINICAL TRIAL TO MEASURE DISPLACEMENT OF Aβ OLIGOMERS INTO CSF NJ Izzo PhD1, KM LaBarbera BS1, CM Yuede PhD2, L Waybright BS1, R Yurko M
Right: Higher CSF concentration of CT1812 was associated with higher CSF concentration of A Os as measured by MIE (open circles) or Western blot (closed squares) in the same patients. CONCLUSION: The results demonstrate the first clinical evidence of target engagement of CT1812 a
Read more →CGTXDisease - modifying medicines for degenerative disorders January 2022 2 This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements
Disease - modifying medicines for degenerative disorders January 2022 2 This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements contained in this presentation, other than statements of hi
Read more →CGTXCognition Therapeutics Reports Third Quarter Financial Results and Company Highlights - Capital from upsized IPO plus substantial NIA grants supports clinical progress of novel small- molecule -2 modulators into new indi
Cognition Therapeutics Reports Third Quarter and Company Highlights - Capital from upsized IPO plus substantial NIA grants supports clinical progress of novel small- molecule -2 modulators into new indications - Purchase, NY - November 18, 2021 - Cognition Therapeutics, Inc.
Read more →Competitive Position
How CGTX ranks across every disease it competes inCompetitive Position is a premium feature
See how CGTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial